citalopram has been researched along with Heart Diseases in 10 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
Heart Diseases: Pathological conditions involving the HEART including its structural and functional abnormalities.
Excerpt | Relevance | Reference |
---|---|---|
"Citalopram daily doses >40 mg were associated with lower risks of ventricular arrhythmia (adjusted hazard ratio=0." | 3.79 | Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg. ( Blow, FC; Bohnert, AS; Ganoczy, D; Kales, HC; Nallamothu, BK; Pfeiffer, PN; Zivin, K, 2013) |
"Citalopram is a selective serotonin reuptake inhibitor (SSRI) antidepressant that is widely used in clinical practice." | 2.49 | Citalopram and cardiac toxicity. ( Cooke, MJ; Waring, WS, 2013) |
"Hydroxychloroquine has been widely prescribed to treat patients with COVID-19 pneumonia." | 1.62 | Torsades de pointes in SARS-CoV-2 (COVID-19) pneumonia: medicine reconciliation and careful monitoring of QTc interval may help prevent cardiac complications. ( Ali, N; Aslam, W; Lamb, CR, 2021) |
"Information on rare adverse effects is often limited when a medication is initially approved for marketing." | 1.56 | Regulatory post-market drug safety advisories on cardiac harm: A comparison of four national regulatory agencies. ( Bhasale, A; Fabbri, A; Hooimeyer, A; McEwin, E; Mintzes, B; Mohammad, A; Perry, L, 2020) |
"The aim of the present study was to compare cardiovascular and/or cardiotoxic effects of eight anti-depressants (imipramine, chlorimipramine, amitriptyline, nortriptyline , doxepin, maprotiline, mianserin and citalopram) in anaesthetized cats after oral dosing and in conscious rabbits after intravenous infusion." | 1.27 | Comparative animal studies on cardiovascular toxicity of tri- and tetracyclic antidepressants and citalopram; relation to drug plasma levels. ( Boeck, V; Fredricson Overø, K; Jørgensen, A, 1984) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (10.00) | 18.7374 |
1990's | 1 (10.00) | 18.2507 |
2000's | 4 (40.00) | 29.6817 |
2010's | 2 (20.00) | 24.3611 |
2020's | 2 (20.00) | 2.80 |
Authors | Studies |
---|---|
Hooimeyer, A | 1 |
Bhasale, A | 1 |
Perry, L | 1 |
Fabbri, A | 1 |
Mohammad, A | 1 |
McEwin, E | 1 |
Mintzes, B | 1 |
Aslam, W | 1 |
Lamb, CR | 1 |
Ali, N | 1 |
Zivin, K | 1 |
Pfeiffer, PN | 1 |
Bohnert, AS | 1 |
Ganoczy, D | 1 |
Blow, FC | 1 |
Nallamothu, BK | 1 |
Kales, HC | 1 |
Cooke, MJ | 1 |
Waring, WS | 1 |
Alexopoulos, GS | 1 |
Kiosses, DN | 1 |
Murphy, C | 1 |
Heo, M | 1 |
Balon, R | 1 |
de Jonge, P | 1 |
Honig, A | 1 |
van Melle, JP | 1 |
Schene, AH | 1 |
Kuyper, AM | 1 |
Tulner, D | 1 |
Schins, A | 1 |
Ormel, J | 1 |
Aström-Lilja, C | 1 |
Odeberg, JM | 1 |
Ekman, E | 1 |
Hägg, S | 1 |
Boeck, V | 1 |
Jørgensen, A | 1 |
Fredricson Overø, K | 1 |
Rasmussen, SL | 1 |
Overø, KF | 1 |
Tanghøj, P | 1 |
2 reviews available for citalopram and Heart Diseases
Article | Year |
---|---|
Citalopram and cardiac toxicity.
Topics: Animals; Citalopram; Dose-Response Relationship, Drug; Heart Diseases; Humans; Long QT Syndrome; Sel | 2013 |
Mood, anxiety, and physical illness: body and mind, or mind and body?
Topics: Anxiety Disorders; Autoimmune Diseases; Citalopram; Comorbidity; Health Status; Heart Diseases; Huma | 2006 |
2 trials available for citalopram and Heart Diseases
Article | Year |
---|---|
Nonresponse to treatment for depression following myocardial infarction: association with subsequent cardiac events.
Topics: Antidepressive Agents; Cardiovascular Diseases; Cause of Death; Citalopram; Comorbidity; Depressive | 2007 |
Cardiac safety of citalopram: prospective trials and retrospective analyses.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Citalopram; Electrocardiography; | 1999 |
6 other studies available for citalopram and Heart Diseases
Article | Year |
---|---|
Regulatory post-market drug safety advisories on cardiac harm: A comparison of four national regulatory agencies.
Topics: Australia; Canada; Citalopram; Databases, Factual; Drug and Narcotic Control; Drug-Related Side Effe | 2020 |
Torsades de pointes in SARS-CoV-2 (COVID-19) pneumonia: medicine reconciliation and careful monitoring of QTc interval may help prevent cardiac complications.
Topics: Aged; Anti-Infective Agents; Citalopram; COVID-19 Drug Treatment; Dexamethasone; Donepezil; Drug The | 2021 |
Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg.
Topics: Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Citalopram; Depressive Disorder; Female; Heart | 2013 |
Executive dysfunction, heart disease burden, and remission of geriatric depression.
Topics: Aged; Antidepressive Agents; Citalopram; Cognition Disorders; Cost of Illness; Depressive Disorder, | 2004 |
Drug-induced torsades de pointes: a review of the Swedish pharmacovigilance database.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Age Factors; Aged; Aged, 80 and over; Ca | 2008 |
Comparative animal studies on cardiovascular toxicity of tri- and tetracyclic antidepressants and citalopram; relation to drug plasma levels.
Topics: Anesthesia; Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Cardiac Output; Cardio | 1984 |